04/15/2026
Most AI systems treat governance as a compliance exercise. Something you document, tick off, and move on from.
We're building things differently.
At Lumiio, governance, transparency, and patient agency are not boxes to check, they are design requirements. Because in rare disease, where communities are small, trust is hard won, and participation is everything, an AI system that does not put patients at the centre will not work. Not ethically, and not practically.
Mel Hayes and Dr. Lawrence Korngut from our team have written about exactly this. What patient-governed AI actually looks like. Why trust is the infrastructure, not a feature. And what it means to build a system where patients are genuine partners in how their data is used.
If you work in rare disease, health AI, or patient advocacy, this one is worth your time.
Read it here: https://www.lumiio.com/news-research/patient-governed-ai-the-trust-infrastructure-rare-disease-will-need-next/
International FOP Association (IFOPA) Inflamed Brain Alliance MitoCanada FSHD Society
By Mel Hayes and Dr. Lawrence Korngut. With contributions from Victoria Hodgkinson, PhD, Blaine Penny, and Ken Kahtava. What This Article Argues In rare disease, the biggest risk in AI is not that it will have a lack of data to provide insights β it is whether those insights can be trusted. As AI ...